Home > Publications Database > Psychiatric Diagnoses and Their Treatment in Women With Breast Cancer: A Latent Class Analysis of 1062 Inpatients. > print

001     274047
005     20250115165651.0
024 7 _ |a 10.1016/j.clbc.2024.06.011
|2 doi
024 7 _ |a pmid:39153934
|2 pmid
024 7 _ |a 1526-8209
|2 ISSN
024 7 _ |a 1938-0666
|2 ISSN
037 _ _ |a DZNE-2025-00028
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Schulze, Jan Ben
|b 0
245 _ _ |a Psychiatric Diagnoses and Their Treatment in Women With Breast Cancer: A Latent Class Analysis of 1062 Inpatients.
260 _ _ |a Dallas, Tex.
|c 2025
|b Cancer Information Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1736940296_13620
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Psycho-oncological support (POS) and psychopharmacological interventions are effective in treating psychiatric symptoms in patients with breast cancer. However, despite high prevalences of psychiatric disorders in patients with breast cancer, a significant proportion remains untreated.Data from 1062 breast cancer patients who had been diagnosed and treated at a Comprehensive Cancer Center between 2012 and 2019 were analyzed retrospectively. We descriptively evaluated the number of patients with a psychiatric diagnosis, POS and psychiatric medication. Latent class analysis was used to examine the relationship between ICD-10 coded psychiatric diagnoses, POS, psychiatric medication, and, as important prognostic factors, tumor stage and somatic comorbidity.31.5% of all patients had a psychiatric diagnosis, 20% received POS and up to 60% received psychiatric medication. Latent class analysis revealed three subgroups: 1) patients with a low cancer stage, low somatic comorbidity, no psychiatric diagnosis, no POS and no psychiatric medication; 2) patients with a low cancer stage, low somatic comorbidity, a psychiatric diagnosis, and a higher probability of POS and psychiatric medication than class 1 and class 3; 3) patients with advanced cancer stage, high somatic comorbidity, a higher probability of a psychiatric diagnosis and POS than class 1, and no psychiatric medication.This study indicated a high prevalence of psychiatric disorders among patients with breast cancer and a discrepancy between the number of patients having a psychiatric disorder and those receiving psychiatric medication. The identification of subgroups might contribute to better tailored treatment for those patients whose needs are insufficiently met.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Breast cancer
|2 Other
650 _ 7 |a Psychiatric comorbidity
|2 Other
650 _ 7 |a Psychiatric medication
|2 Other
650 _ 7 |a Psychiatric treatment
|2 Other
650 _ 7 |a Psycho-oncology
|2 Other
650 _ 7 |a Psychotropic Drugs
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Breast Neoplasms: psychology
|2 MeSH
650 _ 2 |a Breast Neoplasms: therapy
|2 MeSH
650 _ 2 |a Breast Neoplasms: pathology
|2 MeSH
650 _ 2 |a Mental Disorders: epidemiology
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Retrospective Studies
|2 MeSH
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a Latent Class Analysis
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Comorbidity
|2 MeSH
650 _ 2 |a Prevalence
|2 MeSH
650 _ 2 |a Inpatients: psychology
|2 MeSH
650 _ 2 |a Inpatients: statistics & numerical data
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Psychotropic Drugs: therapeutic use
|2 MeSH
700 1 _ |a Dörner, Marc
|0 P:(DE-2719)9002951
|b 1
|u dzne
700 1 _ |a Huber, Mona
|b 2
700 1 _ |a Jordan, Katja-Daniela
|b 3
700 1 _ |a Känel, Roland von
|b 4
700 1 _ |a Euler, Sebastian
|b 5
773 _ _ |a 10.1016/j.clbc.2024.06.011
|g Vol. 25, no. 1, p. e22 - e29
|0 PERI:(DE-600)2175989-3
|n 1
|p e22 - e29
|t Clinical breast cancer
|v 25
|y 2025
|x 1526-8209
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/274047/files/DZNE-2025-00028.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/274047/files/DZNE-2025-00028.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:274047
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002951
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-19
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CLIN BREAST CANCER : 2022
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-19
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-19
920 1 _ |0 I:(DE-2719)1310010
|k AG Schreiber
|l Mixed Cerebral Pathologies and Cognitive Aging
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1310010
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21